United Therapeutics Corporation Monday said that the BEAT clinical study of esuberaprost tablets in patients suffering from pulmonary arterial hypertension did not meet its primary endpoint of delayed time to first clinical worsening event.
Therefore, the company said it has decided to discontinue further esuberaprost development.
The stocks closed on Apr 5, 2019 $120.81.